Summary of COVID-19 razuprotafib studies

105 patient razuprotafib late treatment RCT: 10% higher mortality (p=0.81).
RCT severe COVID-19 patients showing no significant difference in outcomes with razuprotafib.
Mar 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023000664, https://c19p.org/filesraz

2. Paggiarino et al., Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

31 patient razuprotafib late treatment RCT: 178% higher progression (p=0.37) and 469% lower hospital discharge (p=0.28).
RCT 29 patients showing no significant differences with razuprotafib treatment.
Feb 2021, NCT04511650, https://clinicaltrials.gov/study/NCT04511650, https://c19p.org/paggiarino

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0